Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04114695
Other study ID # VEK-nr 66842
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 15, 2019
Est. completion date January 1, 2022

Study information

Verified date March 2022
Source Central Jutland Regional Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Aim and background: This study will seek to identify physiological and biochemical factors explaining and predicting a higher than expected central (aortic) blood pressure (BP) in patients with chronic kidney disease (CKD). The basic hypothesis of the study is that the degree of aortic calcification is an important component of elevated central BP, which, in turn, is important for the organ-damage and increased risk of cardiovascular disease associated with CKD. Methods: Adult patients with varying degrees of CKD undergoing scheduled coronary angiography (CAG) at Aarhus University Hospital will be included in this study. During the CAG procedure, systolic and diastolic BP is determined in the ascending part of aorta by a calibrated pressure transducer connected to the fluid-filled CAG catheter. Simultaneous with the registration of invasive aortic BP, estimation of central BP is performed using radial artery tonometry (SphygmoCor®), while a corresponding brachial BP is also measured. Prior to the CAG, a non-contrast CT scan of aorta in its entirety will be performed to enable blinded quantification of calcification in the wall of aorta and coronary arteries. Furthermore, echocardiography, resting BP measurement and a range of blood- and urine samples will be performed.


Recruitment information / eligibility

Status Completed
Enrollment 185
Est. completion date January 1, 2022
Est. primary completion date January 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age >18 years - Patient referred for planned CAG at the Department of Cardiology, Aarhus University Hospital (AUH) - eGFR constantly either >60 ml/min or <60 ml/min in at least 2 separate blood-sample measurements over at least 3 months. - Signed informed consent-form. Exclusion Criteria: - Antihypertensive treatment changed within the last two weeks prior to the CAG. - Severe aortic valve stenosis (<1 cm) as central hemodynamics may be altered - Maximum number of patients in CKD-group already reached. - Atrial fibrillation or other cardiac arrhythmia making radial Pulse Wave Analysis (PWA) estimations impossible. - Known significant stenosis of a. subclavia or a. brachialis - Bilateral arteriovenous-fistula (even if one or both of these have been surgically removed) as this may significantly affect the pulse-wave form.

Study Design


Locations

Country Name City State
Denmark Aarhus University Hospital Aarhus

Sponsors (1)

Lead Sponsor Collaborator
Central Jutland Regional Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary The difference between directly measured and estimated aortic (central) systolic blood pressure and the corresponding brachial systolic blood pressure Systolic arterial pressure will be determined in the ascending part of aorta using a calibrated pressure transducer connected to the CAG catheter. Simultaneous measurement with af Oscillometric BP-device (Microlife A2 Basic) will be conducted. The difference in mmHg will be calculated. During the CAG-procedure
Primary The degree of aortic calcification The degree of calcification in the wall of the ascending, arcus, descending and abdominal aorta will be measured with a non-contrast CT scan. Agatston-scoring will be applied on the CT images 2 cm after the aortic valve to the aortic bifurcation to ensure that aortic valve calcification is not included in the score. All Agatston scoring will be performed by a radiologist blinded to information on patient biochemical characteristics. CT-scan will be performed prior to CAG if logistically possible and no later than 3 weeks after CAG. All Agatston scoring will be completed when all patients have been included in the study during the summer of 2021.
Primary The difference between directly measured and estimated aortic (central) diastolic blood pressure and the corresponding brachial diastolic blood pressure. Diastolic arterial pressure will be determined in the ascending part of aorta using a calibrated pressure transducer connected to the CAG catheter. Simultaneous measurement with af Oscillometric BP-device (Microlife A2 Basic) will be conducted. The difference in mmHg will be calculated. During the CAG procedure
Secondary Association between Matrix Gla Protein (MGP) and aortic calcification To establish a deeper understanding of the pathogenesis of central arterial calcification in CKD, MGP, a novel biochemical marker of arterial calcification, will be collected and analysed in all patients. Analysis will be performed as batch-analysis at the end of inclusion of patients summer 2021
Secondary Association between Calcification propensity score (T50test) and aortic calcification To establish a deeper understanding of the pathogenesis of central arterial calcification in CKD Calcification propensity score (T50test) will be collected and analysed in all patients. Analysis will be performed as batch-analysis at the end of inclusion of patients summer 2021
Secondary Association between sRANKL (soluble receptor activator of nuclear factor kappa-B ligand) and aortic calcification To establish a deeper understanding of the pathogenesis of central arterial calcification in CKD sRANKL (soluble receptor activator of nuclear factor kappa-B ligand) will be collected and analysed in all patients. Analysis will be performed as batch-analysis at the end of inclusion of patients summer 2021
Secondary Association between 25-OH-Vitamin D(D3+D2) and aortic calcification To establish a deeper understanding of the pathogenesis of central arterial calcification in CKD 25-OH-Vitamin D(D3+D2) will be collected and analysed in all patients. Analysis will be performed as batch-analysis at the end of inclusion of patients summer 2021
Secondary Association between Fetuin-A(alfa-2-Heremans Schmid glycoprotein; AHSG) and aortic calcification To establish a deeper understanding of the pathogenesis of central arterial calcification in CKD Fetuin-A(alfa-2-Heremans Schmid glycoprotein; AHSG) will be collected and analysed in all patients. Analysis will be performed as batch-analysis at the end of inclusion of patients summer 2021.
Secondary Association between Sclerostin and aortic calcification To establish a deeper understanding of the pathogenesis of central arterial calcification in CKD, Sclerostin will be collected and analysed in all patients. Analysis will be performed as batch-analysis at the end of inclusion of patients summer 2021
Secondary Association between osteoprotegerin and aortic calcification To establish a deeper understanding of the pathogenesis of central arterial calcification in CKD, osteoprotegerin will be collected and analysed in all patients. Analysis will be performed as batch-analysis at the end of inclusion of patients summer 2021
Secondary Association between BsAP (bone-specific alkaline phosphatase) and aortic calcification To establish a deeper understanding of the pathogenesis of central arterial calcification in CKD, BsAP (bone-specific alkaline phosphatase) will be collected and analysed in all patients. Analysis will be performed as batch-analysis at the end of inclusion of patients summer 2021
Secondary Association between TRAP5B (tartrate-resistant acid phosphatase 5b) and aortic calcification To establish a deeper understanding of the pathogenesis of central arterial calcification in CKD, TRAP5B (tartrate-resistant acid phosphatase 5b) will be collected and analysed in all patients. Analysis will be performed as batch-analysis at the end of inclusion of patients summer 2021
Secondary Association between P1NP (procollagen type 1 N propeptide) and aortic calcification To establish a deeper understanding of the pathogenesis of central arterial calcification in CKD, P1NP (procollagen type 1 N propeptide) will be collected and analysed in all patients. Analysis will be performed as batch-analysis at the end of inclusion of patients summer 2021
Secondary Association between aortic calcification and Left Ventricular Global Longitudinal Strain (GLS) as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and LVDd (Left ventricular diameter in diastole) as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and IVS (Interventricular septum thickness) as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and Two-dimensional automated evaluation of ejection fraction (2-D auto-EF) as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and Aorta (sinus) diameter as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and Early mitral inflow velocity (E) as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and Duration of Pulmonal Vein Reversal as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and Late mitral inflow velocity (A) as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and Early diastolic mitral annulus velocity (E') as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and PW (Posterior wall thickness) as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and Aorta (ascendens) diameter as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and RVDd (Right ventricular diameter in diastole) as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and LAD (Left atrial diameter) as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and LAV (Left atrial volume) as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and TEI-Index as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association between aortic calcification and Tricuspid annular plane systolic excursion (TAPSE) as determined during echocardiography. All patients included in this study will undergo echocardiography. In particular systolic and diastolic function will be in focus. As scans will be supervised and reanalysed by a cardiologist blinded to patient CKD-stage. No later than 1 month after central BP measurements
Secondary Association of arterial stiffness (defined as Pulse Wave Velocity (PWV)) and aortic calcification To get a non-invasive estimate of arterial stiffness, measurement of Pulse Wave Velocity (PWV) (carotid-femoral and carotid-radial) will be performed. PWV will be recorded with the Sphygmocor® device according to regular protocol. Calibration of the device will be performed using an oscillometric device after 5 minutes of rest. Only measurements with an estimated standard deviation of +/- 1.0 m/s will be accepted and included in the study. If possible, two acceptable measurements will be conducted for each included patient. Calculation of PWV will be performed automatically by the device using a previously published formula. No later than 1 month after Central BP.
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Recruiting NCT05993221 - Deconstructing Post Stroke Hemiparesis